title: In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study.
abstract: OBJECTIVE
  To collect and analyze data on susceptibility of methicillin-resistant staphylococci to evernimicin and other antimicrobial agents.
  
  
  METHODS
  Recent clinical isolates of methicillin-resistant staphylococci from 33 laboratories in North America, Europe and South Africa were investigated.
  
  
  RESULTS
  Of the antimicrobial agents tested, evernimicin had the lowest MIC90s for methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci (0.75 and 1.0 mg/L, respectively). Resistance to ciprofloxacin and erythromycin was widespread, with higher levels of resistance in North America than in other regions.
  
  
  CONCLUSIONS
  Susceptibility surveys help to determine the antimicrobial activity of new agents. Ciprofloxacin- and erythromycin-resistant staphylococci were prevalent throughout all regions.
authors.affiliation: Department of Microbiology, Saint Joseph Hospital at Creighton University Medical Center, Omaha, Nebraska, USA. rgoeri@creighton.edu
authors.forename: R
authors.initials: R
authors.lastname: Goering
authors.forename: C E
authors.initials: CE
authors.lastname: Nord
authors.forename: R
authors.initials: R
authors.lastname: Hare
authors.forename: F
authors.initials: F
authors.lastname: Sabatelli
mesh_terms: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D005060:Europe; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D009656:North America; D013019:South Africa; D013210:Staphylococcus / Q000187:drug effects*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; C001202:evernimicin